Conclusions
This randomized clinical trial failed to support an overarching benefit of bupropion SR compared with placebo when combined with a financial abstinence incentive program. However, differential effects were observed for participants who did and did not achieve early abstinence during an incentive-only study phase, with those who failed to achieve early abstinence benefitting from bupropion SR along with continued financial abstinence incentives. Data suggest that continued examination of bupropion SR with incentives for cocaine abstinence may be warranted and that trials treating stimulant use should account for early abstinence.